|
Interactive data
|
International comparisons
|
OECD Health Statistics 2020
|
|
COVID-19
|
Purchase and consumption of other drugs
|
Ecstasy and Related Drugs Reporting System (EDRS) 2020
|
|
COVID-19
|
Purchase and consumption of alcohol and other drugs
|
National Wastewater Drug Monitoring Program Report 11 2020
|
|
Section 1 – Harm minimisation
|
Supply reduction
|
National Wastewater Drug Monitoring Program Report 11 2020
|
|
Section 1 – Harm minimisation
|
Supply reduction
|
Illicit Drug Data Report 2018–19
|
|
Section 2 – Impacts
|
Health impacts
|
National Hospital Morbidity Database 2018–19
|
|
Section 2 – Impacts
|
Health impacts – Mental health conditions
Health impacts – Injury and hospitalisation
Social impacts – Risky behaviours and criminal activity
|
Ecstasy and Related Drugs Reporting System (EDRS) 2019
|
|
Section 2 – Impacts
|
Health impacts – Injury and hospitalisation
|
National Surveillance System for Alcohol and Other Drug Misuse and Overdose
|
|
Section 2 – Impacts
|
Purchase and consumption of alcohol and other drugs
|
National Wastewater Drug Monitoring Program Report 11 2020
|
|
Section 3 – Drug types
|
Cannabis – Availability
Meth/amphetamine and other stimulants – Availability
Non-medical use of pharmaceutical drugs - Harms
Illicit opioids, including heroin - Availability
New (and emerging) psychoactive substances – Availability
|
Illicit Drug Data Report 2018–19
|
|
Section 3 – Drug types
|
Cannabis – Availability
Meth/amphetamine and other stimulants – Availability, consumption
New and emerging psychoactive substances – Consumption
|
Ecstasy and Related Drugs Reporting System (EDRS) 2019
|
|
Section 3 – Drug types
|
Alcohol - Harms
Cannabis – Harms
Meth/amphetamine and other stimulants – Harms
Non-medical use of pharmaceutical drugs - Harms
|
National Hospital Morbidity Database 2018–19
|
|
Section 3 – Drug types
|
Tobacco - Consumption
Alcohol - Consumption
Cannabis – Consumption
Meth/amphetamine and other stimulants – Consumption
Non-medical use of pharmaceutical drugs – Consumption
Illicit opioids, including heroin – Consumption
New (and emerging) psychoactive substances - Consumption
|
National Wastewater Drug Monitoring Program Report 11 2020
|
|
Section 3 – Drug types
|
Alcohol - Harms
Cannabis – Harms
Meth/amphetamine and other stimulants – Harms
Non-medical use of pharmaceutical drugs – Harms
Illicit opioids, including heroin - Harms
|
National Surveillance System for Alcohol and Other Drug Misuse and Overdose
|
|
Section 4 – Priority populations
|
Aboriginal and Torres Strait Islander people – Illicit drugs, Health and harms, Policy context
|
Aboriginal and Torres Strait Islander Health Performance Framework 2020
|
|
Section 4 – Priority populations
|
People experiencing homelesness
|
Specialist Homelessness Services annual report 2019–20
|
|
Section 4 – Priority populations
|
People in contact with the criminal justice system – Alcohol consumption, Illicit drugs
|
DUMA 2020
|
|
Section 4 – Priority populations
|
People in contact with the criminal justice system –Illicit drugs
|
Illicit Drug Data Report 2018–19
|
|
Section 4 – Priority populations
|
People in contact with the criminal justice system –Illicit drugs
|
Ecstasy and Related Drugs Reporting System (EDRS) 2019
|
|
Section 4 – Priority populations
|
People identifying as lesbian, gay, bisexual, transgender, intersex or queer – Illicit drugs
|
Australian NSP Survey 2019
|